Esophageal cancer Medical Services in China

Esophageal cancer is a malignant neoplasm arising from the epithelial lining of the esophagus—the muscular tube connecting the pharynx to the stomach. It is broadly classified into two histological subtypes: esophageal squamous cell carcinoma (ESCC), predominant in the upper and middle thirds and strongly associated with smoking, heavy alcohol use, and dietary carcinogens (e.g., nitrosamines, thermal injury from hot beverages); and esophageal adenocarcinoma (EAC), which arises predominantly in the distal esophagus and is closely linked to chronic gastroesophageal reflux disease (GERD) and Barrett’s esophagus—a metaplastic change where normal squamous epithelium is replaced by columnar epithelium. Pathogenesis involves progressive accumulation of genetic alterations (e.g., TP53 mutations, CDKN2A inactivation, ERBB2 amplifications) driven by chronic inflammation, oxidative stress, and impaired DNA repair mechanisms. Globally, esophageal cancer ranks sixth in incidence and fifth in cancer-related mortality, with over 600,000 new cases and 540,000 deaths annually (GLOBOCAN 2022). Incidence varies markedly by region: ESCC dominates in the 'Asian Esophageal Cancer Belt'—stretching from northern Iran through Central Asia to northern China—where rates exceed 15–30 per 100,000 person-years; EAC is more common in Western countries, particularly among white males in North America and Northern Europe. Key modifiable risk factors include tobacco smoking (2–5× increased risk), excessive alcohol consumption (especially when combined with smoking), poor nutrition (low intake of fruits/vegetables, micronutrient deficiencies), obesity (for EAC), and habitual consumption of very hot beverages (>65°C). Non-modifiable risks include male sex (3–4× higher incidence), age (>55 years), achalasia, tylosis, and prior head/neck cancers. Early-stage disease is often asymptomatic; dysphagia (initially for solids, progressing to liquids), unintentional weight loss, odynophagia, and retrosternal pain are hallmark late symptoms—leading to frequent diagnosis at advanced stages. This significantly impairs quality of life: patients experience malnutrition, dehydration, social withdrawal due to eating difficulties, anxiety about prognosis, and reduced functional independence. Palliative interventions—including stent placement or feeding tube insertion—may alleviate symptoms but do not reverse systemic decline. Psychosocial burden is high, with elevated rates of depression and caregiver strain. Multidisciplinary management involving gastroenterologists, oncologists, thoracic surgeons, radiation oncologists, and nutritionists is essential to optimize survival and preserve dignity throughout the disease trajectory.

Esophageal cancer arises from malignant transformation of epithelial cells lining the esophagus and is broadly classified into two histologic subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). These entities differ markedly in etiology, epidemiology, and molecular pathogenesis. Common causes include chronic mucosal injury leading to dysplasia and subsequent neoplastic progression. For ESCC, the predominant cause is persistent irritation and inflammation of the squamous epithelium, most frequently driven by tobacco smoking and heavy alcohol consumption—synergistically increasing risk up to 30-fold. Thermal injury from regularly ingesting very hot beverages (>65°C), as classified by the International Agency for Research on Cancer (IARC), is a well-established carcinogenic trigger, particularly in high-incidence regions such as parts of Iran, China, and South America. Nutritional deficiencies—including low intake of fruits, vegetables, zinc, selenium, and certain B vitamins—contribute to impaired DNA repair and oxidative stress, facilitating carcinogenesis. In contrast, EAC predominantly arises from Barrett’s esophagus, a metaplastic change wherein chronic gastroesophageal reflux disease (GERD) induces replacement of normal squamous epithelium with columnar, intestinal-type epithelium. Uncontrolled acid and bile reflux triggers repeated cycles of injury, inflammation, and compensatory proliferation, culminating in dysplasia and adenocarcinoma. Obesity is a major modifiable risk factor for EAC, acting through multiple mechanisms: increased intra-abdominal pressure promoting reflux, systemic low-grade inflammation, and adipokine-mediated insulin resistance and hyperinsulinemia, which stimulate IGF-1 pathways that promote cellular proliferation and inhibit apoptosis. Other significant risk factors include male sex (3–4× higher incidence in men), advancing age (peak incidence 60–70 years), and Caucasian race (for EAC) or Asian/African descent (for ESCC). Genetic factors play a contributory role: while most cases are sporadic, familial clustering occurs, and germline variants in genes such as TP53 (Li-Fraumeni syndrome), CDKN2A (familial atypical multiple mole melanoma syndrome), and BRCA2 confer elevated susceptibility. Genome-wide association studies have identified polymorphisms in ALDH2 (rs671) and ADH1B (rs1229984), particularly prevalent in East Asian populations, which impair acetaldehyde metabolism and markedly amplify ESCC risk in drinkers. Environmental exposures beyond tobacco and alcohol include occupational inhalation of polycyclic aromatic hydrocarbons (e.g., in steelworkers or firefighters), ingestion of nitrosamine-contaminated foods (e.g., pickled vegetables, smoked meats), and exposure to aflatoxin B1 in moldy grains—especially in regions with poor food storage infrastructure. Socioeconomic determinants also influence risk: lower educational attainment and poverty correlate with limited access to nutritious food, delayed diagnosis, and higher prevalence of behavioral risk factors. Prior head and neck cancers, achalasia, caustic esophageal injury (e.g., lye ingestion), and Plummer-Vinson syndrome (iron-deficiency anemia with esophageal webs) further elevate ESCC risk due to chronic stasis, hypoxia, or mucosal atrophy. Human papillomavirus (HPV) infection has been inconsistently associated with ESCC, particularly in high-prevalence geographic areas, though its causal role remains unconfirmed and likely minor compared to tobacco/alcohol. Importantly, the rising global incidence of EAC—particularly in Western nations—is strongly linked to the obesity epidemic and escalating rates of GERD, whereas ESCC incidence is declining in many high-income countries but remains endemic in the so-called 'esophageal cancer belt' stretching from northern Iran through Central Asia to northern China. Prevention strategies therefore require tailored, population-specific interventions targeting modifiable triggers—including smoking cessation, alcohol moderation, dietary optimization, weight management, and timely endoscopic surveillance for Barrett’s esophagus in high-risk GERD patients.

Esophageal cancer—comprising predominantly squamous cell carcinoma (ESCC) and adenocarcinoma (EAC)—is a malignancy arising from the epithelial lining of the esophagus. Its clinical presentation is highly stage-dependent, with early disease often asymptomatic or associated with subtle, nonspecific findings. In the early phase (Tis–T1a), symptoms are frequently absent; when present, they may include intermittent dysphagia to solids only—often misattributed to benign causes such as gastroesophageal reflux disease (GERD) or esophageal spasm. Patients may report a vague sensation of food 'sticking' retrosternally, particularly with coarse or dry foods (e.g., bread or meat), without weight loss or systemic features. Mild odynophagia (painful swallowing) may occur but is uncommon in early stages. Some individuals experience persistent, non-cardiac retrosternal discomfort or burning, mimicking refractory GERD—especially relevant in EAC, where chronic Barrett’s esophagus may precede malignancy. Hoarseness or chronic cough may arise from early involvement of the recurrent laryngeal nerve or tracheobronchial tree, though this typically signals locally advanced disease rather than true early-stage presentation.

Typical symptoms emerge as the tumor grows and obstructs the esophageal lumen (T2–T4). Progressive dysphagia is the hallmark: it begins with solids, advances to soft foods and liquids, and ultimately culminates in near-complete obstruction. This progression over weeks to months is highly suggestive of malignancy and warrants urgent endoscopic evaluation. Odynophagia becomes more frequent and severe, often localized to the level of the tumor and exacerbated by hot or acidic foods. Significant unintentional weight loss (>5% body weight over 6 months) is nearly universal in symptomatic patients due to reduced oral intake, malabsorption secondary to proximal stasis, and cancer-associated cachexia mediated by proinflammatory cytokines (e.g., TNF-α, IL-6). Patients may also develop regurgitation of undigested food, halitosis from retained debris, and aspiration-related symptoms—including nocturnal cough, wheezing, or recurrent pneumonia—particularly with proximal or mid-esophageal lesions causing tracheoesophageal fistula formation.

Accompanying systemic and paraneoplastic symptoms reflect advanced local invasion or metastatic spread. Fatigue, anorexia, and low-grade fever are common. Iron-deficiency anemia may manifest due to chronic occult bleeding from ulcerated tumor surfaces, presenting as pallor, exertional dyspnea, or dizziness. Hoarseness (due to left recurrent laryngeal nerve palsy) and Horner’s syndrome (ipsilateral ptosis, miosis, anhidrosis) suggest mediastinal extension. Superior vena cava syndrome—characterized by facial plethora, neck vein distention, and upper extremity edema—indicates compression or invasion of the SVC by bulky mediastinal disease. Neurologic deficits (e.g., spinal cord compression, headache, visual field defects) may signal hematogenous metastases to bone, brain, or liver.

Complications arise from both tumor biology and therapeutic interventions. Esophagorespiratory fistula—most commonly tracheoesophageal—leads to aspiration pneumonia, bronchitis, and sepsis; it carries a poor prognosis and often precludes curative-intent therapy. Massive hemorrhage, though rare, can occur from tumor erosion into the aorta (especially with posterior wall involvement) or major mediastinal vessels. Esophageal perforation may result from tumor necrosis or iatrogenic injury during endoscopy or dilation. Malignant pleural effusion or pericardial tamponade reflects serosal dissemination. Post-treatment complications include radiation-induced esophagitis, strictures, pulmonary fibrosis, and chemotherapy-related myelosuppression or peripheral neuropathy.

Diagnosis relies on a multimodal approach. Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) remains the gold standard for visualization, biopsy, and staging assessment. High-definition white-light endoscopy with chromoendoscopy (e.g., Lugol’s iodine for ESCC) or narrow-band imaging enhances detection of flat or early neoplastic lesions. Endoscopic ultrasound (EUS) provides precise T- and N-staging by evaluating mural invasion depth and regional lymph node morphology (size, shape, echogenicity, border definition); it enables fine-needle aspiration (FNA) of suspicious nodes. Cross-sectional imaging includes contrast-enhanced CT of the chest/abdomen/pelvis to assess distant metastases (liver, adrenal, lung), locoregional nodal involvement, and vascular encasement. PET-CT is recommended for initial staging in potentially resectable disease to detect occult metastases and guide management decisions. Barium esophagography, while less sensitive for early lesions, demonstrates luminal narrowing, irregular mucosa, and filling defects—and remains useful when endoscopy is contraindicated or incomplete.

Differential diagnosis must exclude both malignant and benign etiologies of dysphagia and upper GI symptoms. Benign strictures (peptic, caustic, or post-radiation), eosinophilic esophagitis (EoE), and achalasia share overlapping features: EoE presents with intermittent dysphagia, food impaction, and ringed esophagus on endoscopy; histology reveals ≥15 eosinophils/hpf. Achalasia manifests with progressive dysphagia to solids and liquids, regurgitation of undigested food, and absence of peristalsis on manometry. Peptic strictures demonstrate concentric narrowing in the distal esophagus with underlying GERD symptoms and respond to PPI therapy. Other malignancies include gastric cardia adenocarcinoma (which may involve the distal esophagus secondarily), lymphoma, and metastatic disease (e.g., melanoma, breast, lung). Non-malignant inflammatory conditions—such as infectious esophagitis (Candida, HSV, CMV) in immunocompromised hosts—present with odynophagia and endoscopic exudates or ulcers but lack mass lesions. Mediastinal tumors (e.g., lymphoma, thymoma) may cause extrinsic compression, distinguishable via CT/MRI showing displacement rather than intrinsic wall thickening. Crucially, any patient aged ≥50 years with new-onset dysphagia, especially with weight loss or iron-deficiency anemia, requires prompt endoscopic evaluation to exclude esophageal cancer—given its high mortality when diagnosed at late stages.

Esophageal cancer is a malignant neoplasm arising from the epithelial lining of the esophagus, with squamous cell carcinoma (ESCC) predominant in the upper and middle thirds—especially in high-incidence regions such as northern China—and adenocarcinoma (EAC) more common in the distal esophagus and gastroesophageal junction, often associated with chronic gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Accurate staging via endoscopic ultrasound (EUS), contrast-enhanced CT, PET-CT, and sometimes bronchoscopy or laparoscopy is essential to guide therapeutic decisions. Treatment strategies are highly stage-dependent and must be individualized based on tumor histology, location, extent (T/N/M status), patient performance status, comorbidities, and patient preference.

Conservative (non-surgical) management is indicated for patients with unresectable locally advanced disease, metastatic disease, or those unfit for surgery due to significant cardiopulmonary compromise or frailty. Definitive chemoradiotherapy (dCRT) remains the standard of care for medically inoperable, localized ESCC (Stage II–III), typically comprising concurrent cisplatin-based chemotherapy (e.g., cisplatin 75 mg/m² IV day 1 + 5-fluorouracil 1000 mg/m²/day IV continuous infusion days 1–4 and 29–32) with radical radiotherapy (50–50.4 Gy in 25–28 fractions). For EAC, dCRT is less established but may be considered in select cases; neoadjuvant therapy followed by surgery remains preferred when feasible. Palliative radiotherapy (30–40 Gy in 10–15 fractions) effectively alleviates dysphagia, bleeding, or pain in advanced disease. Endoscopic palliation—including argon plasma coagulation (APC), Nd:YAG laser ablation, photodynamic therapy (PDT), or self-expanding metal stents (SEMS)—provides rapid symptomatic relief for malignant obstruction, particularly in patients with short life expectancy or contraindications to systemic therapy.

Pharmacologic interventions encompass both cytotoxic and targeted agents. Platinum-fluoropyrimidine doublets (e.g., cisplatin/5-FU or oxaliplatin/capecitabine) form the backbone of first-line systemic therapy for metastatic or recurrent disease. Immunotherapy has revolutionized treatment: pembrolizumab is FDA- and NMPA-approved as first-line therapy for PD-L1–positive (CPS ≥10) unresectable or metastatic ESCC, either as monotherapy or combined with platinum-based chemotherapy. Nivolumab plus ipilimumab or nivolumab plus chemotherapy are also approved options. For HER2-positive EAC (≈15–20% of cases), trastuzumab combined with chemotherapy improves overall survival. Emerging agents include Claudin 18.2-targeted therapies (e.g., zolbetuximab) in clinical trials for gastric/esophagogastric junction adenocarcinoma. Supportive medications—including proton pump inhibitors (e.g., esomeprazole 40 mg daily) for GERD control, antiemetics (e.g., palonosetron + aprepitant), nutritional supplements (e.g., oral peptide-based formulas), and opioid analgesics for refractory pain—are integral to comprehensive care.

Surgical resection remains the only potentially curative modality for resectable esophageal cancer (Stage I–III). The procedure of choice is esophagectomy, most commonly performed via Ivor Lewis (transthoracic) or McKeown (three-incision) approaches for mid/distal tumors, or transhiatal esophagectomy for cervical/upper thoracic lesions. Minimally invasive esophagectomy (MIE), including robotic-assisted techniques, is increasingly adopted in specialized centers, offering reduced blood loss, shorter hospital stays, and lower pulmonary complication rates without compromising oncologic outcomes. Lymphadenectomy is critical: two-field (mediastinal + abdominal) dissection is standard for ESCC; three-field (adding cervical nodes) may be considered for proximal tumors. Reconstruction utilizes gastric pull-up (most common), colonic interposition, or jejunal interposition depending on anatomy and prior surgery. Neoadjuvant therapy—either chemoradiation (for ESCC) or chemotherapy alone (for EAC per CROSS and FLOT4-AIO trials)—is strongly recommended for clinically staged cT1b–cT4a, N0–N+ disease, significantly improving R0 resection rates and long-term survival.

China offers distinct advantages in esophageal cancer management. First, China hosts the world’s largest cohort of ESCC patients, fostering unparalleled clinical expertise and high-volume surgical centers—such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center—where surgeons perform >200 esophagectomies annually, correlating with superior perioperative outcomes. Second, China’s National Medical Products Administration (NMPA) has accelerated approval pathways for novel immunotherapies; pembrolizumab, camrelizumab, and tislelizumab are all approved for ESCC within months of global data release. Third, integrated traditional Chinese medicine (TCM) is routinely incorporated—not as alternative therapy but as adjunctive supportive care—to mitigate chemotherapy-induced myelosuppression (e.g., Jia Wei Xiao Yao San), improve appetite (e.g., Shen Ling Bai Zhu San), and reduce radiation esophagitis (e.g., Yin Qiao San modifications), supported by randomized trials published in journals like *Chinese Journal of Cancer Research*. Fourth, China’s centralized health information systems enable longitudinal follow-up and real-world evidence generation, informing national guidelines updated biannually by the Chinese Society of Clinical Oncology (CSCO).

Post-treatment recovery requires multidisciplinary coordination. Patients should undergo structured swallowing rehabilitation with speech-language pathologists starting preoperatively and continuing for ≥6 weeks post-esophagectomy to prevent strictures and aspiration. Nutritional support is paramount: small, frequent, soft-textured meals; avoidance of bolus foods and carbonated beverages; supplementation with vitamin B12, iron, calcium, and fat-soluble vitamins (A/D/E/K) due to malabsorption risk. Regular surveillance includes upper endoscopy every 6–12 months for the first 3 years (to detect metachronous lesions or anastomotic recurrence), annual chest/abdominal CT, and serum tumor markers (SCC for ESCC; CEA/CA19-9 for EAC). Psychosocial support—including smoking cessation counseling (mandatory, given strong synergism with alcohol and tobacco), depression screening (PHQ-9), and peer-led survivorship groups—is embedded in national quality-of-care standards. Long-term survivors must be counseled on late effects: dumping syndrome (managed with dietary modification and acarbose), bile reflux (treated with bile acid sequestrants), and increased risk of second primary cancers (especially head/neck and gastric), warranting lifelong endoscopic surveillance. Adherence to evidence-based follow-up protocols correlates with 5-year overall survival exceeding 65% in Stage II and 45% in Stage III disease at leading Chinese centers.